Kalaris Therapeutics Q2 net loss narrows on lower administrative costs

Kalaris Therapeutics

11/08/2026 13:12

Overview
US retinal disease drug developer's Q2 net loss and loss per share beat analyst expectations
Operating income for Q2 showed a slight beat versus analyst estimates
Cash reserves fell to $93.5 mln, expected to fund operations into Q4 2027

Outlook
Kalaris expects preliminary data from Phase 1b/2 TH103 study in 1H 2027
Company plans to initiate potential Phase 3 trials by year-end 2027
Kalaris expects cash to fund operations into Q4 2027 and through key clinical milestones

Result Drivers
CLINICAL TRIAL EXPANSION - Higher research and development expenses were mainly due to increased clinical activity for TH103, including opening more investigational sites and enrolling patients
MANUFACTURING COSTS - R&D expense growth was partially offset by decreased manufacturing and process development spending
LOWER ADMINISTRATIVE COSTS - General and administrative expenses declined due to decreased legal, accounting, and other professional fees

Company press release: ID:nGNXbT5mF0

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Beat
$0.48
$0.50 (8 Analysts)
Q2 Net Loss
Beat
$11.52 mln
$12.14 mln (7 Analysts)
Q2 Operating Income
Slight Beat*
-$12.39 mln
-$12.49 mln (6 Analysts)
Q2 Operating Expenses
 
$12.39 mln
 
*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Kalaris Therapeutics Inc is $18.50, about 369.5% above its August 10 closing price of $3.94

Reuters Recommended Reads
Aug 10 - Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Aug 10 - Metagenomi Q2 net loss widens cash runway seen through 2027
Aug 11 - Eye care company Alcon raises margin outlook, shares jump

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)